PsA Raises Mortality Risk, but Unevenly Some psoriatic arthritis patients more vulnerable than others in Swedish study Dec 04, 2023
New Data on Bimekizumab in Psoriatic Arthritis Roundtable of experts weigh in on "unprecedented" efficacy, and safety issues Nov 29, 2023 video
Methotrexate Tied to Greater Risks for Older Patients With CKD FDA should consider warning labels based on study results, researchers argue Nov 28, 2023
New Data on TYK2 Inhibitors for Psoriasis, Psoriatic Arthritis Favorable results with TAK-279 and deucravacitinib in studies at ACR Nov 22, 2023 video
Novel IL-17A Blocker Continues to Impress in PsA More phase II data build case for izokibep Nov 14, 2023
Stelara Biosimilar OK'd With Interchangeability But patent settlement may keep new product off market until 2025 Nov 01, 2023
Link Between Psoriasis, Heart Disease Tracks to Coronary Microvascular Dysfunction Lower coronary flow reserve associated with severity, duration of psoriasis Sep 20, 2023
Tool Predicts PsA Progression From Psoriasis, No Fancy Biomarkers Needed New model estimates risk from routine clinical parameters Aug 09, 2023
TNF Blockers for IBD Tied to Risk for Immune-Mediated Diseases "Paradoxical" finding puzzles researchers Jul 22, 2023
Make the Diagnosis: What Caused this Childโs Knee Lesions? A mother brought her 7-year-old son to the doctor concerned about asymptomatic lesions that had developed on his knees over the past couple of weeks. May 24, 2023
High Rates of Psoriasis Clearance With Investigational TYK2 Inhibitor Rates of 90% clearance approaching 50% at 12 weeks, with 100% clearance rates as high as 33% Mar 21, 2023
Biologic Switch Revs Up Response in Plaque Psoriasis "Dramatic improvement" at 16 weeks with IL-23 blocker after lack of response to anti-IL-17 drug Mar 19, 2023
Psoriatic Arthritis: Depressing News on Second- and Later-Line Treatments Real-world data indicate most patients who fail a first biologic drug never obtain remission Feb 27, 2023
First TYK2 Inhibitor for Psoriasis Wins FDA Approval Deucravacitinib significantly outperformed apremilast in two randomized trials Sep 11, 2022
First Approved Treatment for Generalized Pustular Psoriasis Spesolimab led to complete clearance of pustules within a week in more than half of patients Sep 07, 2022
Study: Flares in Pustular Psoriasis Often Undertreated Drug firm hopes to bring new specific treatment to market Aug 10, 2022
Asian Psoriasis Patients Get Less Time With Dermatologists, Study Suggests Cross-sectional study shows Asian patients have shortest face-to-face visits Aug 03, 2022
Chronic, Disfiguring Facial Rash With No Itching or Pain Female patient reports low quality of life after 10 years of treatments with no response Jul 11, 2022
Which Biologics Stick Longest for Psoriasis? British data highlight factors affecting drug longevity Jul 06, 2022
Novel IL-17 Inhibitor Passes Mid-Stage Test in Psoriatic Arthritis Phase II results suggest drug could outperform existing agents Jun 03, 2022
Lance Bass' Psoriatic Arthritis "I just figured it was because of dancing," says former member of 'NSYNC May 26, 2022
FDA OKs First Novel Nonsteroidal Topical for Plaque Psoriasis in 25 Years Complete, near-complete clearance in 35-40% of patients treated with tapinarof cream 1% May 24, 2022
Response in Kids With Psoriasis Maintained Long Term With IL-17A Inhibitor At least 75% improvement at 108 weeks in patients treated with ixekizumab Apr 13, 2022
Psoriasis Therapy Has Mixed Effects on Cardiovascular Risk Factors No reduction in vascular inflammation with apremilast but significant reduction in body fat Mar 30, 2022
Toward More Uniform Methotrexate Dosing in Psoriasis International expert group urges common standards Mar 30, 2022
Two Years On, Tremfya Still Shines in Psoriatic Arthritis Efficacy increases in long-term extension data Feb 10, 2022
Psoriasis Patients, Docs Want to Do More to Prevent Heart Problems Despite well-known cardiovascular risks, most patients currently undertreated Jan 19, 2022
How Should Patients With Autoimmune Diseases Approach COVID Vaccination? Mixed messaging and a lack of tailored research leaves providers and patients in the dark Oct 22, 2021
Rates of Serious Infection Differ Among Psoriasis Therapies Low overall rate, small differences versus etanercept reference, large French study showed Jul 22, 2021
Target TNF or IL-12/23 in Psoriatic Arthritis? Both TNF inhibitors and ustekinumab were effective in real-world use Jun 30, 2021
Methotrexate Impairs COVID Vax Response Can extra vaccine doses or discontinuing drug benefit patients with immune-mediated diseases? May 25, 2021
Plaque Psoriasis Drug Shows Promise for Psoriatic Arthritis Monoclonal antibody targets the IL-23 p19 subunit May 20, 2021
For Safety, One Biologic a Winner in Psoriasis, Psoriatic Arthritis Lower hospitalization rates compared with other biologics or small molecule therapies May 19, 2021
Drug 'TYKs' All the Boxes in Two Plaque Psoriasis Trials Significantly higher response rates with TYK2 inhibitor deucravacitinib versus apremilast Apr 25, 2021
Big Win in Psoriasis for Dual IL-17A/17F Inhibitor Significant differences in clearance with bimekizumab vs secukinumab at all time points Apr 23, 2021
For Enthesitis in Psoriatic Arthritis, Target IL-23 Targeted agent provides relief for many PsA patients Apr 08, 2021
JAK Inhibitor Promising in Psoriatic Arthritis Oral agent noninferior to adalimumab in joint symptoms Apr 01, 2021
Don't Stop Taltz in Psoriatic Arthritis Significantly more patients relapsed, and more quickly, after withdrawal Mar 10, 2021
Monoclonal Antibody Highly Effective in Phase III Psoriasis Trial Beats ustekinumab, but main side effect was oral candidiasis Feb 05, 2021
